Press Releases
Entellus Medical Launches XprESS LoProfile Multi-Sinus Dilation Tool with Light Fiber
January 21, 2013
MINNEAPOLIS, MINNESOTA — (January 21, 2013) —Entellus Medical, a leading manufacturer of innovative tools for treating patients with chronic and recurrent sinusitis, launched its XprESS LoProfile Multi-Sinus Dilation Tool. The reduced profile is designed to more easily navigate tight sinus spaces and facilitate quick and easy dilation of multiple sinus drainage paths, allowing physicians to potentialy treat more patients with in-office procedures or reduced OR time.
To view the full press release, click here.
Study Shows Physicians can Reliably Access and Dilate Maxillary Sinus Openings with Entellus Medical’s XprESS
September 10, 2012
MINNEAPOLIS, MINNESOTA — (September 10, 2012) —Results from a study presented by Dr. David Brodner during the 58th Annual Meeting of the American Rhinologic Society in Washington D.C. demonstrate that both newly trained and experienced users of the Entellus Medical™ XprESS™ Multi-Sinus Dilation Tool can consistently and successfully access and dilate the natural maxillary sinus opening without need for tissue removal. These results affirm the unique utility and ease of use of a balloon sinus dilation device to open the most commonly inflamed sinus drainage path without cutting sinus tissue.
To view the full press release, click here.
Entellus Medical Launches PathAssist™ Light Seeker™ to Help ENT Physicians Navigate Frontal Sinus Passages
FDA-cleared, Light-based Tool Will Aid Office and OR Sinus Procedures
September 12, 2011
MINNEAPOLIS, MINNESOTA — (September 12, 2011) —Entellus Medical, a Minnesota-based medical technology company, today announced the launch of its PathAssist™ Light Seeker™ at the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery in San Francisco. The Light Seeker, which received clearance from the U.S. Food and Drug Administration in June 2011, enables ENT physicians to easily confirm correct entry to the frontal sinus recess and location of the frontal sinus, helping streamline procedures such as sinus irrigation and endoscopic sinus surgery.
To view the full press release, click here.
Research Presented at ENT Rhinology Conference Adds to the Clinical Evidence Supporting Entellus Medical’s FinESS™ Sinus Treatment
Studies Confirm Office-Based Balloon Sinus Dilation Delivers Significantly Improved Quality of Life for Chronic Sinusitis Patients
September 12, 2011
MINNEAPOLIS, MINNESOTA – (September 12, 2011) - Entellus Medical, a Minnesota-based medical technology company, announced today that results of two clinical research studies presented at the annual American Rhinologic Society meeting in San Francisco support the efficacy of Entellus Medical’s™ FinESS™ Sinus Treatment, a balloon dilation procedure for chronic sinusitis.
To view the full press release, click here.
Entellus Medical™ completes series E financing totaling $35 million
August 17, 2011
MAPLE GROVE, MN - (August 17, 2011) - Entellus Medical Inc., a medical device company that markets minimally invasive solutions for treatment of patients with chronic sinusitis, today announced the completion of a $35 million round of fund raising. The new financing was led by Covidien Ventures, who joined existing investors SV Life Sciences, Essex Woodlands, Split Rock Partners, and Greenspring Associates. Proceeds from the financing will be used to fund the company’s ongoing operations and commercialization of Entellus’ multiple product lines, which are used by Ear, Nose, & Throat (ENT) physicians to dilate narrowed or obstructed sinus drainage pathways.
To download the full press release, click here.
Entellus Medical™ study demonstrates XprESS™ Multi-Sinus Dilation Tool safe and effective in treatment of chronic sinusitis
April 28, 2011
MINNEAPOLIS – (April 28, 2011) – Results presented by Dr. David Brodner today during the annual Combined Otolaryngology Spring Meeting in Chicago demonstrate that Entellus Medical's XprESS multi-sinus dilation tool may be used safely and with a high technical success rate in conjunction with traditional functional endoscopic sinus surgery (FESS) tools to treat patients with chronic sinusitis. Further, one-month data show patients experience a statisticaly significant improvement in quality of life related to their sinusitis symptoms.
To download the full press release, click here.
Study shows that employee chronic sinusitis sufferers and their employers benefit from balloon dilation of sinus drainage pathways
Minimally invasive sinus procedure reduces absenteeism and improves worker productivity
March 30,2011
MINNEAPOLIS – (March 30, 2011) – Results published in the January/February, 2011 issue of International Forum of Allergy & Rhinology demonstrate that patients with chronic rhinosinusitis (CRS) who receive treatment with balloon sinus dilation can experience significant improvement in work productivity. Prior to treatment, patients reported a 38% loss in productivity due to sinusitis symptoms that resulted in absenteeism and reduced on-the-job effectiveness. Twelve months after balloon dilation of the sinus drainage pathways using FinESS™ Sinus Treatment, patients reported a reduction of absenteeism and lost work productivity of 73% to 76%.
According to Brian Farley, CEO of Entellus Medical, “This study demonstrates the toll of sinusitis symptoms on worker productivity, and the potential of Entellus’ FinESS Sinus Treatment to dramatically reduce patient absenteeism, activity impairment, and work limitations. We are very pleased that these patients, who often are in the prime of their wage-earning years, and their employers, are able to benefit from a procedure that can be performed quickly and successfully in the doctor’s office.”
In the report titled, “Impact of chronic rhinosinusitis on work productivity through one-year follow-up after balloon dilation of the ethmoid infundibulum,” subjects reported the quantity, quality and timeliness of their work output was limited 33% of the time due to CRS, and significantly impacted their absentee rate. Treatment with balloon-only sinus dilation dramatically reduced the impact of CRS on productivity, and patients experienced on average a 70% improvement in quality of life related to sinusitis symptoms.
To download the full press release, click here.
Entellus MedicalTM Receives FDA 510(k) Clearance for FinESSTM Endoscope
February 23, 2011
MINNEAPOLIS, MN, (February 23, 2011) --Entellus Medical, a Minnesota-based medical technology company, announced today that the U.S. Food and Drug Administration cleared the company’s new FinESS Endoscope. The endoscope is used with the FinESS Sinus Treatment, which employs minimally-invasive balloon dilation to open narrowed sinus drainage paths and relieve symptoms in patients with recurrent or chronic sinusitis. The new Entellus endoscope enables treatment of sinusitis patients in the doctor’s office by delivering enhanced image quality and visualization of the sinus thereby potentially reducing procedure time.
The Entellus FinESS system treats the two most commonly inflamed sinuses, the maxillary and anterior ethmoid sinuses. Designed to be performed in the doctor’s office setting, FinESS is the only balloon dilation system on the market that predictably allows direct visualization of the maxillary sinus opening. This ensures treatment of the natural sinus drainage pathways.
According to Entellus Medical CEO Brian Farley, “Our new endoscope provides ENT physicians a clear visual perspective to quickly guide sinus balloon catheter placement and successfully treat patients in the doctor’s office. This practice-changing technology greatly enhances the treatment options for physicians and their patients who suffer from sinusitis.”
To download the full press release, click here.
Entellus Medical Settles Patent Dispute
February 17, 2011
MAPLE GROVE, MN, (February 17, 2011) -- Entellus Medical today announced that it has entered into a licensing agreement with Acclarent, Inc. in order to resolve their patent lawsuit. The license agreement is royalty bearing to Acclarent. Additional financial details were not disclosed.
As part of the agreement, the companies will file a joint request for the termination of a patent infringement proceeding brought by Acclarent against Entellus on July 28, 2010 in the U.S. District Court for the Northern District of California.
“We are pleased to have reached a mutually beneficial arrangement,” said Brian Farley, Entellus President and CEO.
To download the full press release, click here.
Entellus Medical Study Demonstrates that Balloon Dilation to Treat CRS can be Performed Safely in the Clinic with Symptoms Improvements
September 25, 2010
MINNEAPOLIS - (September 25, 2010) - Entellus Medical, a Minnesota-based medical technology company, shared the results of a 12-month study entitled "Clinic versus OR - A Comparative Analysis of Ostial Dilation for CRS," presented on September 25th during the 56th annual meeting of the American Rhinologic Society in Boston, Mass.
The study, authored by Jeffrey Cutler M.D., Colorado Sinus Institute, Denver, Colo., analyzed the results of 71 patients who underwent balloon dilation to treat chronic sinusitis (CRS) and were followed for 12 months after the procedure. Nineteen (27%) of these patients were treated in the clinic. Intra-operative and long-term outcomes were compared between patients treated in the operating room and those treated in the clinic.
Procedure times and procedural success were similar while total facility time was significantly less for the clinic cohort. All (100%) clinic patients were discharged within 2 hours of the procedure as compared with 82% of the operating room cohort. There was no signficant difference between the two groups in post-treatment bleeding, overall recovery time and post-treatment pain medication use. Both groups showed statistically signficant and clinically meaningful improvement in their sinus-related symptoms. In the first year following treatment, revision surgery was performed on 3.8% of patients treated in the OR vs. 0% of patients treated in the clinic.
According to Dr. Cutler, "Balloon dilation in the clinic provides physicians with a tool to treat persistent sinus disease without requiring general anesthesia and these results demonstrate that dilation of the sinus drainage pathways in the clinic is safe and well-tolerated by patients and provides long-term relief of sinus-related symptoms."
To download the full press release, click here.
Adoption of Entellus Medical® XprESS™ Multi-Sinus Dilation Tool Gains Traction with ENTs Across U.S.
September 22, 2010
MINNEAPOLIS - (September 22, 2010) - Entellus Medical, a Minnesota-based medical technology company, announced that its new multi-sinus dilation tool XprESS™ is being widely accepted and used by ear, nose and throat (ENT) physicians. Introduced in April of this year, XprESS has been adopted by hundreds of ENTs and used in successful sinus surgeries across the country.
According to Entellus Medical CEO Brian Farley, "We are very please with how quickly the market has adopted the XprESS Multi-Sinus Dilation Tool. ENT physicians tell us they appreciate the value in the intuitive design of XprESS, which combines the capabilities of a seeker, balloon dilation, suction and irrigation to treat multiple sinuses in one easy-to-use multi-functional tool."
To download the full press release, click here.
Entellus Medical® Launches the XprESS™ Multi-Sinus Dilation Tool at COSM 2010 Annual Meeting
April 28, 2010
Farley Named President and CEO of Entellus Medical®
April 27, 2010
Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis
March 17, 2009
Entellus Medical Names Brian E. Farley to Board
November 11, 2008
Entellus Medical Launches FinESS™ Sinus Treatment at American Academy of Otolaryngology (AAO) Annual Meeting
September 22, 2008
Entellus Medical Secures $15 Million Financing To Commercialize a New Sinus Surgery Alternative
June 9, 2008
